Actively Recruiting
Treatment Guideline for Patients Undergoing Second or More Allogeneic Stem Cell Transplant Using Reduced Intensity Conditioning with Busulfan, Fludarabine, and Low Dose Total Body Irradiation
Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-07-06
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate a treatment guideline for patients undergoing a second or greater allogeneic hematopoietic stem cell transplant HSCT using a reduced intensity conditioning RIC regimen. It is intended for patients with non-malignant or malignant hematologic disorders, hemoglobinopathies, or immunodeficiencies who have not achieved sufficient donor-derived engraftment after a previous transplant. The goal is to promote successful engraftment in these challenging cases. Participants will receive a conditioning treatment consisting of busulfan given intravenously every 6 hours on Days -8 and -7, fludarabine intravenously on Days -6 through -2, and a low dose of total body irradiation 200 cGy on Day -1. On Day 0, participants will receive the stem cell transplant infusion. Keppra will be administered during busulfan treatment to help prevent seizures. This treatment guideline does not include experimental research beyond collecting routine clinical data. During the study, participants will be monitored through routine clinical data collection maintained in specialized transplant databases. Researchers will measure the time to engraftment by Day 42 and assess additional outcomes such as graft failure, donor chimerism status, acute and chronic graft-versus-host disease, transplant-related mortality, and overall survival at various time points up to one year. Participants may be followed for up to several years as part of this observational data collection to evaluate transplant outcomes and safety.
CONDITIONS
Brief Title
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Research Team
T
Troy Lund, M.D., Ph.D.
P
Paul Orchard, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here